---
created: 2025-04-13
updated: 2025-04-13T10:52
id: OPf~DL}gk?
specialty: immuno
specialty_id: 250
tags:
  - source/ak-original-decks::step-1::zanki-step-decks::zanki-immunology-+-general-pathology::immunology
  - source/ak-step1-v11::
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies
  - source/ak-step1-v11::
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::ixekizumab
  - source/ak-step1-v11::
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::secukinumab
  - source/ak-step1-v11::
  - source/ome-banner::basic-science::07-immunology
  - source/ak-step1-v11::
  - theme/pixorize::01-immunology::04-b-&-t-cells::14-th17
  - source/ak-step1-v11::$ankingadds::fa2020::immunology
  - source/ak-step1-v11::^other::^highyield::5-lowyield
  - source/ak-step1-v11::^systems::immunology::akadds"
type: flashcard
---

# Question
**Ixekizumab** and **secukinumab** are monoclonal antibodies against **IL-17A** used to treat psoriasis and psoriatic arthritis

---

# Answer
